Puma's Debt-Free Inflection: How a Single-Product Biotech Self-Funds a Phase III Pivot
NERLYNX posts a second consecutive growth year as Puma clears its final debt payment and repurposes the cash into alisertib.
PBYI · Earnings Call · 2026-08-06
The Debt Wall Comes Down
The headline of Puma's Q2 report isn't a single drug stat — it's the state of the balance sheet. The company made its final quarterly principal payment of $11.1M on the Athyrium obligation during the quarter, exiting debt-free with roughly $93.9M of cash, cash equivalents, and marketable securities. CFO Maximo Nougues delivered it almost casually:
As a result, Puma now is debt-free.
That changes the strategic game entirely. This has long been a single-product company — NERLYNX in HER2-positive breast cancer — funding an investigational pipeline (alisertib) around the margins. Now CEO Alan Auerbach is explicit that the freed-up cash flow pays for the next stage: pivotal Phase III trials in both ER-positive breast and small-cell lung, even if they have to be staggered to protect the net-income line.
“we probably have to stagger them… It is completely achievable.” — Alan H. Auerbach, Chief Executive Officer, President and Chairman of the Board · 2026-08-06
The numbers back the narrative. Liabilities-to-assets have collapsed from a 98% peak in 2022 to 33.4%, and effective net cash turned strongly positive:
Effective net cash rose to $65M (up 205% year-over-year), a direct product of the final Athyrium payoff and sustained commercial generation.
Commercial Strength, With a China Caveat
The commercial engine is what makes the pivot possible. Net NERLYNX product revenue came in at $53.6M, up 28% sequentially from Q1's $42M. Critically, most of that was real demand: the Q2 inventory drawdown was only $1.3M versus $7.9M in Q1, while U.S. demand grew 8% quarter-over-quarter and 11% year-over-year. Management flagged a genuine first — 2026 will mark the first time in U.S. launch history that NERLYNX posts back-to-back annual demand increases.
“the first time in the history of the launch of NERLYNX in The United States, that we have seen 2 positive consecutive year over year increases in demand.” — Alan H. Auerbach, Chief Executive Officer, President and Chairman of the Board · 2026-08-06
That strength funded a guide-up — full-year NERLYNX product revenue raised to $205M-$209M and net income to $17M-$20M. But the royalty picture carries a documented overhang: the China sublicense royalty rate steps down when generic NERLYNX market share crosses a threshold, and management now says that could happen in late 2026 or 2027.
“we believe it is possible that the threshold could be reached triggering the royalty rate reduction in late 2026 or in 2027.” — Maximo F. Nougues, Chief Financial Officer · 2026-08-06
With full-year royalty guidance trimmed to $19M-$22M, the royalty mechanics are a real drag on the partner-revenue line even as core product sales accelerate.
From One Trial to a Program
The most interesting shift this quarter is how alisertib has gone from a single-trial story to a portfolio. The keyword momentum tells the tale: the once-dominant “ALISCA Lung1” theme fell out of momentum this quarter, replaced by a broader “Interim data” framing and the declaration of a brand-new trial, ALISCA Lung 2, a combo study with paclitaxel modeled on the prior Journal of Thoracic Oncology randomized trial.
Trial design is now encoding biomarker conviction. ELISCA-Breast1 is being amended to drop the 30mg dose arm entirely, keeping only the 40mg and 50mg doses where the company sees better activity in aurora-kinase-pathway positive (c-Myc) patients. In lung, dosing has escalated to 70mg BID with 92 patients enrolled. This matches the preliminary indication management has been teasing for two quarters.
“we are seeing a much better signal in the patients where there’s a signal of c-Myc positivity” — Alan Auerbach, Chief Executive Officer, President and Chairman of the Board · 2026-05-08
The Phase III ambition is now explicitly tied to the balance sheet, echoing a prediction Auerbach made in November 2025:
“the debt goes away mid next year, and we become a debt-free company… It’s still possible to be able to do a pivotal Phase III just based on the cash flow from NERLYNX.” — Alan Auerbach, Chief Executive Officer, President and Chairman of the Board · 2025-11-07
The cost of this ambition is a deliberate R&D ramp — guided up 34% to 37% for the year, with R&D already reaching $18.9M in Q2.
R&D expense is the deliberate counterpart to the debt-free windfall, guided up 34-37% for 2026 as trials progress.
The company reiterated the discipline that's kept the model profitable through the transition:
“we are committed to maintaining… positive net income. If we have to stagger the trials, then we can stagger.” — Alan H. Auerbach, Chief Executive Officer, President and Chairman of the Board · 2026-08-06
Verdict
The tape has been telling a muted version of this story — the stock is still down ~96% from its 2014 peak but is up roughly 19% over the past three months as the market begins to price in a sustainable commercial base plus a self-funded pipeline. For a $356M-market-cap biotech, the combination of a debt-free balance sheet, back-to-back commercial growth, and a credible Phase III roadmap is a genuine inflection. The swing factors to watch: whether the China royalty cliff lands in 2026/2027, and whether the upcoming ALISCA Lung 2 plus further interim data keep the biomarker thesis intact. If the aurora-kinase signal holds, the market’s implied probability of success on the pipeline could keep repricing upward.